Your session is about to expire
← Back to Search
Pembrolizumab for Thyroid Cancer
Study Summary
This trial is testing a new immunotherapy drug to see if it can extend the lives of patients with an aggressive form of thyroid cancer who have no other treatment options.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.I have previously been treated with specific immunotherapy drugs.I have a history of HIV, Hepatitis B, or Hepatitis C.My thyroid cancer has spread, but it's either been fully removed by surgery or doesn't need neck surgery/radiation.I have not received a live vaccine in the last 30 days.I have not had radiotherapy in the last 2 weeks.I have received a transplant from a donor.I've had radiation or surgery for my tumor and now have ATC/UTC.My hemoglobin level is high enough without needing blood transfusions or medications to increase it.I have or had lung inflammation not caused by infection, treated with steroids.You have a disease that can be measured using specific guidelines.You have a strong allergic reaction to pembrolizumab or any of its ingredients.My cancer can be measured by scans and has grown in previously treated areas.My thyroid cancer cannot be removed by surgery or has spread.I haven't had cancer treatment in the last 4 weeks.I am 18 years old or older.I am currently being treated for an infection.My thyroid cancer is confirmed to be anaplastic or undifferentiated.You have other medical conditions, mental health issues, or problems with drugs or alcohol.I do not have active brain metastases or cancer in the lining of my brain, with some exceptions.I have no other cancers needing treatment in the past year.I have an autoimmune disease but haven't needed systemic treatment in the last 2 years.Your blood and body chemistry need to be within certain ranges.I have an immune system disorder or have been on steroids or other immune-weakening drugs in the last week.Your platelet count is at least 100,000 per microliter within 10 days before starting the treatment with pembrolizumab.Your absolute neutrophil count should be at least 1500 per microliter within 10 days before starting the pembrolizumab treatment.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.My kidney function tests are within the required range.
- Group 1: Pembrolizumab 200 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the United States Food and Drug Administration granted authorization for Pembrolizumab (Keytruda)?
"Despite lacking evidence of efficacy, the safety profile of Pembrolizumab (Keytruda) was judged to be a 2 due to existing clinical data."
Are there any open enrollments for this research initiative?
"Affirmative. According to records on clinicaltrials.gov, this medical trial is currently hunting for participants which was initially posted on February 15th 2022 and updated most recently two days later. They must procure 20 patients from one site alone."
How many volunteers are enrolled in this experiment?
"That is accurate. As reflected on clinicaltrials.gov, the trial began enrollment in mid-February and has been actively recruiting since then; 20 volunteers are needed from a single site for this medical research project."
Under what circumstances is Pembrolizumab (Keytruda) typically prescribed?
"Pembrolizumab (Keytruda) is commonly administered to treat malignant neoplasms, as well as other diseases such as unresectable melanoma, microsatellite instability high and chemotherapy-resistance."
Are there any precedents of Pembrolizumab (Keytruda) being tested in clinical trials?
"Currently, the clinical trial landscape for Pembrolizumab (Keytruda) is quite robust with 961 active studies and 122 in Phase 3. Of particular note, Houston, Texas holds a large number of these trials at 35731 locations but other areas are also participating."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger